{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196467","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.433026+00:00","generated_at":"2026-05-31T11:05:58.390388+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cabaletta Bio Q2: $203.2M cash, 9 patients enrolled, Grade 4 ICANS DLT resolved","bullets":["R&D expenses $23.4M (Q2 2023: $11.8M); G&A $6.9M (Q2 2023: $4.1M).","Cash, equivalents and ST investments $203.2M, expected to fund ops into H1 2026.","Nine patients enrolled across RESET program as of Aug 5; 22 U.S. sites now active.","LN patient with active refractory disease had Grade 4 ICANS DLT; IDMC recommended study proceed at current dose.","New Lonza CDMO agreement and expanded Cellares partnership for CABA-201 manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196467","json":"https://secwatch.observer/filing/0001193125-24-196467.json","markdown":"https://secwatch.observer/filing/0001193125-24-196467.md","text":"https://secwatch.observer/filing/0001193125-24-196467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312524196467/0001193125-24-196467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312524196467/d884570d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:05:58.390388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}